Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Parenthetical]

v3.8.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Parenthetical] - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Accrued Liabilities   $ 374,000 $ 474,000
Debt Conversion, Converted Instrument, Shares Issued 60,000 32,456  
Payments of Stock Issuance Costs $ 695,000    
Business Combination, Contingent Consideration, Liability     $ 2,600,000
Celleration, Inc [Member]      
Accrued Liabilities   $ 675,000  
Debt Conversion, Converted Instrument, Shares Issued 101,243    
Choice Therapeutics [Member]      
Accrued Liabilities   $ 500,000  
Debt Conversion, Converted Instrument, Shares Issued 131,579    
Common Stock [Member]      
Stock Issued During Period, Shares, Acquisitions 101,243 [1] 98,594 [2]  
[1] Includes $675,000 that was part of contingent consideration as of December 31, 2016, which was credited to equity upon the issuance of 101,243 common shares during the year ended December 31, 2017.
[2] Includes $2.6 million that was part of contingent consideration as of December 31, 2015, which was credited to equity upon the issuance of 98,594 common shares during the year ended December 31, 2016.